ReviewFrontiers in endocrinology2020
New Therapies for Advanced Thyroid Cancer.
Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Unraveling the connection and pathogenesis of systemic lupus erythematosus and thyroid cancer: integrative meta-analysis, Mendelian randomization, and transcriptomic insights.Clinical rheumatology · 2026Pooled it
- Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Association between vitamin D status and thyroid cancer: a meta-analysis.Frontiers in nutrition · 2024Pooled it
- Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review.Computational and mathematical methods in medicine · 2022Pooled it
- The impact of classical music on anxiety and pain perception during a thyroid fine needle aspiration biopsy.Hormones (Athens, Greece) · 2023Trial
- FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- MicroRNA-181a-5p promotes papillary thyroid carcinoma progress via the PTEN/AKT pathway.Molecular biotechnology · 2026Article
- General Assessment of Indole Derivatives and Wnt Pathway as Potential Key Factors Against Various Diseases, with Particular Emphasis on Thyroid Tumors.International journal of molecular sciences · 2026Review
- When Suspicious Thyroid Cytology Isn't Thyroid Cancer: Multinodular Goiter With Granulomatous Lymphadenopathy.Cureus · 2026Article
- COPZ1 depletion induces cell death through different mechanisms in in vitro murine models of thyroid cancer.European thyroid journal · 2026Article
- DLEU2 promotes the migration and invasion of papillary thyroid carcinoma cells through the ELAVL1/RCC2 axis.Functional & integrative genomics · 2026Article
- Integrative Bioinformatics Analysis Reveals COL13A1 and COL23A1 as Potential Diagnostic and Prognostic Biomarkers in Thyroid Cancer.Health science reports · 2026Article
- C6orf15 expression in thyroid tumors: A promising diagnostic biomarker for the classic variant of papillary thyroid carcinoma.Histology and histopathology · 2026Article
- Integrated multi-omics and single-cell analysis reveals CDKN2A-mediated cuproptosis mechanisms driving thyroid carcinoma progression.NPJ systems biology and applications · 2026Article
- Network toxicology and Mendelian randomization reveal pathogenic factors of monoethyl phthalate-induced thyroid cancer.European thyroid journal · 2026Article
- Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy.Cancers · 2026Review
- Development of a prognostic model for thyroid cancer based on mitochondrial metabolism-related genes and immune profiling.World journal of surgical oncology · 2026Article
- Crosstalk between the microbiome and immune microenvironment in the pathogenesis and treatment of thyroid carcinoma: a narrative review.Frontiers in immunology · 2026Review
- Determination of protein markers of inflammasome formation and ferroptosis in thyroid cancer based on gender.Journal of Cancer · 2026Article
- Transferrin receptor serves a role in promoting PANoptosis in thyroid cancer.Oncology letters · 2026Article
98 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for thyroid cancer has significantly improved the understanding of the molecular pathogenesis of thyroid cancer, thus allowing more personalized treatments for patients with thyroid cancer. Most of the recently discovered targeted therapies inhibit the known oncogenic mechanisms in thyroid cancer initiation and progression such as MAPK pathway, PI3K/Akt-mTOR pathways, or VEGF. Despite the significant advances in molecular testing and the discoveries of new and promising therapeutics, effective treatments for advanced and metastatic, iodine-refractory thyroid cancer are still lacking. Here, we aim to summarize the current understanding of the genetic alterations and the dysregulated pathways in thyroid cancer and to discuss the most recent targeted therapies and immunotherapy for advanced thyroid cancer with a promising anti-tumor activity and clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.